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ABSTRACT
Background
A C1173T polymorphism in intron 1 of the VKORC1 gene has been claimed to determine the
interindividual variability in the response to vitamin K antagonist therapy (VKA), but it is
unknown whether it also influences bleeding risk. We aimed to confirm the relationship
between C1173T status and phenprocoumon or acenocoumarol use, and to examine the risk of
severe bleeding for the various genotypes.
Methods and Findings
We studied this in a case-control study of 110 patients who bled during VKA therapy and 220
control patients free of bleeding under the same therapy. To achieve the same target INR, CT
genotype and TT genotype control patients required less phenprocoumon (CC genotype 2.9
mg/d [95% confidence interval (CI): 2.6–3.2], CT genotype 2.6 mg/d [95% CI: 2.1–3.1], TT
genotype 1.4 mg/d [95 % CI: 1.1–1.7]) or acenocoumarol (CC genotype 3.2 mg/d [95% CI: 2.9–
3.5], CT genotype 2.3 mg/d [95% CI: 2.1–2.5], TT genotype 1.7 mg/d [95% CI: 1.3–2.1]) than CC
genotype control patients. Compared with CC genotype individuals, carriers of at least one T
allele had an increased risk of bleeding in the phenprocoumon users (crude odds ratio ¼ 2.6,
95% CI: 1.2–5.7), but not in acenocoumarol users (crude odds ratio ¼ 1.2, 95% CI: 0.6–2.3).
Conclusion
These findings encourage taking further steps towards the evaluation of the use of VKORC1
genetic testing for bleeding prevention in individuals who receive VKA therapy.
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Vitamin K antagonists such as warfarin, acenocoumarol,
and phenprocoumon are commonly used for the prevention
and treatment of venous and arterial thrombosis. The
molecular target of these anticoagulants is the vitamin K
epoxide reductase complex of which the precise composition
is largely unknown. Recently, one component of this complex,
the vitamin K epoxide reductase complex subunit 1
(VKORC1), was identiﬁed by positional cloning [1]. This
VKORC1 gene is mutated in individuals with combined
deﬁciency of vitamin K-dependent clotting factors type 2 or
with warfarin resistance [1,2].
The required dose of antagonist in vitamin K antagonist
therapy (VKA) to achieve a target level of anticoagulation is
variable, in particular between individuals, but also within a
single individual, and depends on, for example, dietary intake
and variations in pharmacokinetics. Earlier this year, poly-
morphisms in the VKORC1 gene have been reported that
explain up to 30% of the variability in the pharmacological
response to VKAs [3–5].
Bleeding is an important complication of treatment with
VKA. In The Netherlands, intensive efforts by anticoagulation
clinics are aimed at monitoring treatment with phenprocou-
mon and acenocoumarol, the two VKAs that are registered
for use. These efforts are largely focussed on maintaining the
level of anticoagulation, generally expressed as the interna-
tional normalized ratio (INR), within a speciﬁed target range.
In these efforts, individual patient characteristics such as
those related to inherited determinants of the pharmaco-
logical response are only indirectly taken into account. We set
out to estimate the contribution of a C1173T polymorphism
in the VKORC1 gene to the acenocoumarol and phenprocou-
mon dose requirement and to the bleeding risk.
Methods
For the present analyses we used DNA from a previously
reported case-control study [6]. This study includes 110
patients classiﬁed as ‘‘severe bleeders’’ and 220 ‘‘non-
bleeders’’ (more than 96% of the participants are Caucasian)
who were selected from two anticoagulation clinics. Major
bleeding was deﬁned as a bleeding that was clinically overt and
met one of the following criteria: associated with a haemo-
globin drop of  20 g/l, hospitalization, blood transfusion of
two or more units, intracranial bleeding, intramuscular
bleeding, intra-articular bleeding, or intraocular bleeding.
Bleeders and non-bleeders were visited at home, during which
a questionnaire was completed and blood was collected for the
preparation of plasma and DNA. Genotyping for the C1173T
polymorphism in the VKORC1 gene was performed using a
simple restriction enzyme digestion of PCR-ampliﬁed DNA.
Details of the protocol are available from the corresponding
author upon request. Statistical analyses were performed for
acenocoumarol and phenprocoumon separately and com-
bined. We calculated odds ratios as measures of relative risks
from the contingency table as the exposure odds ratios (OR),
with 95% conﬁdence intervals (CI) based on the assumption of
a Poisson distribution, according to Woolf [7]. The institu-
tional review boards of the Academic Medical Center and the
Leiden University Medical Center approved the study proto-
col, and all patients gave written informed consent.
Results
Table 1 shows the dose requirements for the same target
INR categorized for the different genotypes in controls. The
data conﬁrm the claims that were made in three earlier
papers [3–5]. In comparison to CC genotype carriers, the
average dose of acenocoumarol or phenprocoumon was
15%–30% less in CT heterozygotes, and about 40% less in
homozygous TT individuals. There does not seem to be a
major difference between acenocoumarol and phenprocou-
mon in this respect. The results are similar in the cases (data
not shown).
Next we examined whether the C1173T genotype inﬂu-
enced the bleeding risk (Table 2). Overall the OR for major
haemorrhage for carriers of at least one T-allele was 1.7 (95%
CI: 1.1–2.5). When analysed separately, phenprocoumon
seems to more strongly modify the bleeding risk of the
C1173T genotype (OR ¼ 2.6 [95% CI: 1.2–5.7 for T-allele
carriers]), whereas in acenocoumarol users the genotype had
little effect (OR ¼ 1.2 [95% CI: 0.6–2.3]). When we add all
controls together in the calculations of the odds ratios in
order to obtain statistically more stable results (which is
reasonable because genotype does not inﬂuence the pre-
scription), the ORs for bleeding in T-carriers are 1.4 (95 % CI:
0.8–2.5) for acenocoumarol and 2.1 (95% CI: 1.1–4.2) for
phenprocoumon.
We examined the quality of anticoagulation in the various
groups of genotypes and VKAs. The percentage of time in
range was considerably higher in phenprocoumon treated
controls (CC genotype 60% in range (95% CI: 45–75, CT/TT
genotype 66% in range (95% CI: 62–71) than in individuals
treated with acenocoumarol (CC genotype 41% in range
(95% CI: 35–47, CT/TT genotype 46% in range (95% CI: 42–
51), whereas genotype had no appreciable effect on time in
range.
Discussion
The results, although based on a small sample size of
individuals with bleeding, support the suggestion that the
bleeding risk for T-carriers is higher in phenprocoumon than
in acenocoumarol users. If this ﬁnding is conﬁrmed in
additional studies and extended to the more frequently
occurring and clinically relevant cases of nonmajor bleeding,
it may imply that CT and TT carriers should be preferentially
treated with acenocoumarol despite the fact that the
genotype-related excess bleeding in phenprocoumon users
is not mediated through unstable anticoagulation that is
detected by the INR, because genotypes were associated with
Table 1. Relationship between C1173T Genotype and VKA Mean
Daily Dose Requirement in Control Patients
VKORC1 Genotype
C1173T
Acenocoumarol,
mg/d (95% CI; n)
Phenprocoumon,
mg/d (95% CI; n)
CC 3.2 (2.9–3.5; 55) 2.9 (2.6–3.2; 40)
CT 2.3 (2.1–2.5; 57) 2.6 (2.1–3.1; 29)
TT 1.7 (1.3–2.1; 23) 1.4 (1.1–1.7; 12)
The mean daily dose was calculated by dividing the sum of all daily doses by the number of treatment days.
DOI: 10.1371/journal.pmed.0020312.t001
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treatment is better in phenprocoumon than in acenocou-
marol users, which is in agreement with previous publications
[8]. This paradox—apparently good INR control by all
measures, but higher bleeding risks in phenprocoumon-
treated patients—has been reported before, in particular in
relationship to minor bleeding [8].
At present we have no clear explanation for risk differ-
ences between the two coumarin anticoagulants. It is unlikely
that these drugs have differential effects on the carboxylation
status of vitamin K–dependent clotting factors. In support of
this, levels of factors IX (which do not inﬂuence the INR) are
similar between the two treatment groups (data not shown).
More likely, a difference in bleeding risk may ﬁnd an
explanation in the vastly different pharmokinetics of aceno-
coumarol (biological half-life ¼ 11 h) and phenprocoumon
(half-life ¼ 140 h). Receivers of anticoagulants are often frail
people with signiﬁcant health problems. Perhaps alterations
in their health status that affect coumarin sensitivity are not
effectively managed with a long half-life product.
The increased bleeding risks give support to the notion that
genotyping for this polymorphism in the VKORC1 gene may
go beyond an academic interest and may become standard for
every individual starting on acenocoumarol and phenpro-
coumon treatment. It may help in the identiﬁcation of those
individuals who are at the highest bleeding risk and thus
should be monitored more intensely. Such VKORC1 testing
may need to be complemented with testing for Cyp2C9
polymorphisms, which also inﬂuence the pharmacokinetics of
VKAs and for which there is also increasing evidence for a
relevant relationship between genotype and bleeding [9].
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Patient Summary
Background Patients who have experienced blood clots or who are at
risk of getting clots are often put on anticoagulant treatment to reduce
the ability of blood to clot efficiently. One group of these drugs works by
interfering with the action of vitamin K, which is essential for blood
clotting. The disadvantage of this type of drug is that the treatment has
to be monitored closely to ensure that it does not work too well, in
which case a patient may have bleeding, or not well enough, in which
case the blood may clot.
Why Was This Study Done? Previous work has suggested that a change
in one of the genes involved in blood clotting, VKORCI, might affect how
well these drugs work. The authors wanted to confirm this finding and
see if changes in the gene also affect how likely patients are to bleed
when given the drugs.
What Did the Researchers Do and Find? They looked at 110 people
who had bled after being given the anticoagulants and 220 who had not.
They found that one particular variation in the gene resulted in people
requiring less anticoagulation medicine. This same variation also meant
that some people were more likely to bleed with one of the
anticoagulant drugs, but not with another.
What Do These Findings Mean? If these findings are confirmed in
studies of other groups of patients, they suggest a reason why patients
vary so much in their response to anticoagulation and why some people
bleed whereas others do not. In the future, it may be possible to look at
the genes in patients given anticoagulation to help make decisions
about their treatment.
Where Can I Get More Information Online? MedlinePlus has
information on blood clots and the drugs used to treat them:
http://www.nlm.nih.gov/medlineplus/bleedingdisorders.html
Anticoagulation Europe is a site specifically for people taking anti-
coagulants:
http://www.anticoagulationeurope.org/
Table 2. Numbers of Cases and Controls for the Different
VKORC1 Genotypes and Crude ORs for Bleeding under VKA
Treatment
VKORC1
Genotype
a
Acenocoumarol Phenprocoumon
Cases,
n
Controls,
n
OR
(95% CI)
Cases,
n
Controls,
n
OR
(95% CI)
CC 22 55 1 13 40 1
CT
26 57
1.1
(0.4–1.7) 25 29
2.7
(1.2–6.0)
TT
13 23
1.4
(0.6–3.2) 10 12
2.6
(0.9–7.3)
CT and TT
39 80
1.2
(0.6–2.3 35 41
2.6
(1.2–5.7)
CT and TT
(combined
controls) 39 121
1.4
(0.8–2.5) 35 121
2.1
(1.1–4.2)
aThe assay failed in five individuals. Therefore the genotypes for 325 individuals are given.
DOI: 10.1371/journal.pmed.0020312.t002
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